13 studies found for:    Open Studies | spectrum pharmaceuticals
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
Condition: Biliary Cancer
Intervention: Drug: SPI-1620 & Docetaxel
2 Recruiting A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL
Condition: Acute Lymphoblastic Leukemia (ALL)
Interventions: Drug: Vincristine Sulfate Liposomes Injection (VSLI);   Drug: Vincristine Sulfate Injection (VSI)
3 Recruiting Phase 2, Single Arm, Open Label Study of Folotyn in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With PTCL
Conditions: Relapsed Peripheral T-Cell Lymphoma;   Refractory Peripheral T-Cell Lymphoma
Interventions: Drug: Folotyn and Leucovorin;   Drug: Folic Acid;   Drug: Vitamin B12
4 Recruiting Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Condition: Peripheral T-cell Lymphoma
Interventions: Drug: Belinostat;   Drug: CHOP
5 Recruiting Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Conditions: Refractory Non Hodgkin Lymphoma;   Relapsed Non Hodgkin Lymphoma
Interventions: Biological: rituximab;   Biological: ibritumomab tiuxetan;   Biological: anti-thymocyte globulin;   Radiation: total nodal irradiation;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
6 Recruiting Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
Conditions: Leukemia;   Lymphoma
Interventions: Drug: Rituximab;   Drug: 111In Ibritumomab;   Procedure: Planar Scintigraphy Imaging;   Drug: 90Y IbritumomabTiuxetan;   Drug: Fludarabine;   Drug: Bendamustine;   Drug: Thymoglobulin;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Mycophenolate;   Drug: G-CSF;   Procedure: Stem Cell Transplantation
7 Recruiting Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
Condition: Leukemia
Interventions: Drug: Rituximab;   Drug: Imatinib;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Mesna;   Drug: VSLI;   Drug: Solu-Medrol;   Drug: Methotrexate;   Drug: Ara-C;   Drug: G-CSF;   Drug: Pegfilgrastim;   Drug: Dexamethasone
8 Recruiting Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
Conditions: Brain Metastases;   Non-small Cell Lung Cancer
Intervention: Drug: Lucanthone
9 Recruiting Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis
Condition: Hematological Malignancy
Interventions: Drug: Cohort 1-Bortezomib (Velcade ®);   Drug: Cohort 2-Bortezomib (Velcade ®);   Drug: Cohort 3-Bortezomib (Velcade ®)
10 Recruiting Pheno- & Genotyping POF (WHO III)
Conditions: Premature Ovarian Failure (POF);   Incipient Ovarian Failure;   Poor Response After Ovarian Hyperstimulation;   Early Menopause;   Hypergonadotropic Amenorrhea
Intervention:
11 Recruiting Behavioral Treatment of Adolescent Substance Use
Condition: Substance Use Disorders
Interventions: Behavioral: Behavior Therapy;   Behavioral: Working Memory Training
12 Recruiting Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission
Condition: Neuroblastoma in Remission
Intervention: Drug: DFMO
13 Recruiting Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma
Condition: Neuroblastoma- Relapsed and Refractory
Interventions: Drug: DFMO;   Drug: Bortezomib

Indicates status has not been verified in more than two years